Effects of Chronic Antihypertensive Treatment with Ketanserin Versus Metoprolol on Blood Pressure and Large Arteries' Compliance in Humans: A Cross-Over Double-Blind Study
- 1 April 1988
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 28 (4), 332-338
- https://doi.org/10.1002/j.1552-4604.1988.tb03154.x
Abstract
The antihypertensive efficacy of a serotonin‐receptor antagonist, ketanserin, was compared with that of a well‐established antihypertensive drug, metoprolol, and their cardiac and forearm hemodynamic effects were investigated using echocardiography and bidimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive subjects completed a double‐blind, cross‐over, randomized study using ketanserin and metoprolol. Two 5‐week courses with ketanserin or metoprolol were preceded by a placebo period; the total duration of the study was 15 weeks. Despite a comparable efficacy in reducing systolic and diastolic blood pressure (about 10% of the basal value), the two drugs showed quite different effects on forearm hemodynamics. Ketanserin increased forearm blood flow and induced a significant decrease in forearm vascular resistance (from 141 ± 16 to 75 ± 11 mm Hg/mL/sec, P < .01). Furthermore, this treatment was able to improve brachial artery compliance (from 1.89 ± .3 to 3.2 ± .3 cm4/dyne 10‐7, P < .01). On the contrary, metoprolol did not modify forearm hemodynamics. Both drugs did not significantly modify cardiac performance, as evaluated by left ventricle circumferential fiber shortening. Cardiac output was increased by ketanserin (from 5.9 ± .3 to 6.6 ± .5 L/min, P < .05) and fell during treatment with metoprolol (from 5.9 ± A to 4.9 ± .3 L/min P < .01). Thus, the two drugs reduce blood pressure through different hemodynamic mechanisms and the effects of ketanserin on systemic and peripheral circulation seem more favorable.Keywords
This publication has 20 references indexed in Scilit:
- Impaired responsiveness of the ventricular sensory receptor in hypertensive patients with left ventricular hypertrophy.Circulation, 1986
- Cardiovascular Effects of Ketanserin, A New Antiserotonergic Agent in the Treatment of Arterial HypertensionThe Journal of Clinical Pharmacology, 1985
- Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension.Heart, 1984
- Alpha 1 antagonistic and antiserotoninergic action during administration of ketanserin.BMJ, 1983
- Mechanism of antihypertensive action of ketanserin in man.BMJ, 1983
- Ketanserin, a novel 5‐hydroxytryptamine antagonist: monotherapy in essential hypertension.British Journal of Clinical Pharmacology, 1983
- Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agentJournal of Pharmacy and Pharmacology, 1982
- Pulsed Doppler: determination of diameter, blood flow velocity, and volumic flow of brachial artery in manCardiovascular Research, 1981
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Recommendations for Human Blood Pressure Determination by SphygmomanometersCirculation, 1967